Letter: Journal Glut

In his letter to The Scientist, (Oct. 16, 1989, page 15) in response to my essay, "The Journal Glut" (The Scientist, July 10, 1989, page 11), Allan Wittman correctly recognizes that much of the original essay was written tongue-in-cheek. But humor is frequently only a funny way of being serious. Wittman says the proliferation of scientific journals represents both an increase in scientific information and the essential need for scientists to know what other scientists are doing. In fact, appro

Written byJeffrey Moran
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

In his letter to The Scientist, (Oct. 16, 1989, page 15) in response to my essay, "The Journal Glut" (The Scientist, July 10, 1989, page 11), Allan Wittman correctly recognizes that much of the original essay was written tongue-in-cheek. But humor is frequently only a funny way of being serious.

Wittman says the proliferation of scientific journals represents both an increase in scientific information and the essential need for scientists to know what other scientists are doing. In fact, approximately three fourths of the papers published in legitimate scientific journals receive less than half a dozen citations in the first 10 years after publication. What can we conclude from this? Perhaps most of those papers should not have been published in the first place.

Many of these "noncited" papers amount to little more than filling up blank spaces in tables of data; they should be recognized as such and relegated ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies